Skip to main content

Table 1 Demographic and baseline medical characteristics (ME population)

From: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

 

Tigecycline N = 247

Imipenem/Cilastatin N = 255

Mean ± SD age, years

42.9 ± 18.0

43.1 ± 17.6

Sex, n (%) male

173 (70.0)

166 (65.1)

Ethnic origin, n (%)

  

   White

104 (42.1)

106 (41.6)

   Black

16 (6.5)

25 (9.8)

   Asian

30 (12.1)

30 (11.8)

   Hispanic

54 (21.9)

44 (17.3)

   Other

43 (17.4)

50 (19.6)

Mean ± SD weight, kg

70.3 ± 15.7

69.3 ± 15.9

Mean ± SD creatinine clearance, mL/min

94.2 ± 35.3

94.3 ± 34.1

Mean ± SD therapy duration, days

8.1 ± 2.8

7.9 ± 2.7

Mean APACHE II score

5.6

5.5

Primary intra-abdominal diagnosis, n (%)

  

   Complicated appendicitis

152 (61.5)

145 (56.9)

   Perforation of intestine

21 (8.5)

23 (9.0)

   Complicated diverticulitis

17 (6.9)

25 (9.8)

   Intra-abdominal abscess

17 (6.9)

17 (6.7)

   Peritonitis

14 (5.7)

16 (6.3)

   Gastric/duodenal perforation

13 (5.3)

10 (3.9)

   Complicated cholecystitis

12 (4.9)

16 (6.3)

   Other*

1 (0.4)

3 (1.2)

  1. *Other diagnoses included infected hematoma, pelvic inflammatory disease, acute abdomen subocclusion, acute inflammatory abdomen, disease pelvic infectious, tubo-ovarian abscess, right tubal abscess, infected left subphrenic hematoma.